PJP
Invesco Pharmaceuticals ETF
Set alert
130.54 USD +1.66 +1.29%
130.30 Day range 131.88
95.58 52-week range 131.64
- YTD
- +24.87%
- 1 year
- +36.58%
- Open
- 130.83
- Prev close
- 128.88
- Mkt cap
- 373.96M
- Vol
- 52.09K
- Avg vol
- 33.65K
- EPS
- 5.59
- P/E
- 23.35
- Div yield
- 0.00%
More statistics
- Low
- 130.30
- High
- 131.88
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 86.39
- 200-d avg
- 83.44
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 24.87
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 86.39
- 200-day average
- 83.44
About Invesco Pharmaceuticals ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. The underlying index is composed of common stocks of U.S. pharmaceutical companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
News
- What's Going On With Amgen Stock Tuesday?
- Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
- Amgen Posts 77% Response In Thyroid Eye Disease Study
- Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial
- Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
- Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
- Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
- Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
- Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
- Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Your note
Sign in to keep a note on PJP — it syncs with the Stock Master app.